A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer

Advanced Cancer Clinical Trial

Official title:

A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02507544
• Other study ID #: CVM-001
• Status: Completed
• Phase: Phase 1
• Start date: September 2015
• Est. completion date: May 20, 2019

Study information

• Verified date: May 2020
• Source: TaiRx, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

TRX-818 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. TRX-818 is a potent anti-cancer agent in numerous human cancer cell lines. The objectives of this study are to determine the safety profile of TRX-818 including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD) and determine the recommended dose and regimen(s) to initiate Phase 2.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: May 20, 2019
• Est. primary completion date: April 29, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Tumor eligibility:

Histologically confirmed advanced malignancies refractory to standard of care therapy, or for whom no standard of care therapy is available.

2. Solid tumors must have measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST v. 1.1). Target lesions that have been previously irradiated will not be considered measurable (lesion) unless increase in size is observed following completion of radiation therapy. Leukemia, lymphomas and multiple myeloma must have measurable disease as per response criteria.

3. Female or male, 18 years of age or older.

4. Eastern Cooperative Oncology Group performance status 0 to 2. Resolution of all acute toxic effects of prior therapy or surgical procedures to grade 1 (except alopecia).

5. Adequate organ function as defined by the following criteria:

• Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) =3 x upper limit of normal (ULN), or AST and ALT =5 x ULN if liver function abnormalities are due to underlying malignancy

• Total serum bilirubin =1.5 x ULN (except for patients with documented Gilbert's syndrome)

• Absolute neutrophil count (ANC) >= 1500/µL

• Platelets >= 90,000/µL

• Hemoglobin >= 9.0 g/dL

• Serum creatinine =2.0 x ULN

6. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.

7. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria:

Patients presenting with any of the following will not be included in the trial:

1. Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of starting study treatment.

2. Prior high-dose chemotherapy requiring hematopoietic stem cell rescue except for patients with lymphoma or myeloma.

3. Current treatment on another clinical trial.

4. Brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease unless appropriately treated and neurologically stable for at least 4 weeks.

5. Any of the following within the 12 months prior to starting study treatment:

myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack; within 6 months prior to starting study treatment for pulmonary embolus. However, upon agreement between the investigator and sponsor, the 6 month post-event-free period for a patient with a pulmonary embolus can be waived if due to advanced cancer. Appropriate treatment with anticoagulants is permitted.

6. Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy).

7. Current treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg Per oral (PO) daily for deep vein thrombosis prophylaxis is allowed).

8. Known human immunodeficiency virus infection.

9. Pregnancy or breastfeeding. Female patients must be surgically sterile or be postmenopausal, or must agree to the use of effective contraception during the period of therapy. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.

10. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, which would make the patient inappropriate for entry into this study.

Related Conditions & MeSH terms

• Advanced Cancer
• Carcinoma
• Neoplasms

Intervention

Drug:
• TRX-818 capsules

Locations

Country	Name	City	State
United States	START Midwest	Grand Rapids	Michigan
United States	South Texas Accelerated Research Therapeutics, LLC (START)	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
TaiRx, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limiting toxicity (DLT) of TRX-818	Toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0.	up to 28 days
Primary	Maximum tolerated dose (MTD) of TRX-818	The MTD will be defined as the dose level at which at most one of six patients experiences a DLT after 28 days of treatment have occurred, with the next higher dose having at least 2/3 or 2/6 patients experiencing a DLT.	up to 28 days
Secondary	Preliminary assessment of anti-tumor activity by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)		up to 112 days
Secondary	Composite measure of pharmacokinetics (PK) parameters of TRX-818 and its metabolites TRX-818M1 to include AUC(0-last), Cmax, Tmax, T(1/2).	AUC(0-last): area under the plasma concentration versus time curve to the time of the last measurable concentration; Cmax: maximum plasma concentration; Tmax: time to maximum plasma concentration; T(1/2): terminal elimination half-life	Selected time points during first 28 days
Secondary	Time to tumor progression (TTP)		up to 112 days